What are the precautions for taking acalabrutinib/acalabrutinib?

Acalabrutinibis a kinase inhibitor indicated for the treatment of mantle cell lymphoma who have received at least one prior therapy(MC L)Patients, also used to treat chronic lymphocytic leukemia(CLL) or small lymphocytic lymphoma(SLL).

What are the precautions for taking acalabrutinib/acalabrutinib(Acalabrutinib)?

1.Serious and opportunistic infections. Fatal and serious infections, including opportunistic infections, have occurred in patients with hematological malignancies receivingacabrutinib. Consider prophylaxis for patients at increased risk for opportunistic infections and monitor patients for signs and symptoms of infection and treat promptly.

2.Bleeding. Fatal and serious bleeding events have occurred in patients with hematological malignancies receiving acalabrutinib. Concomitant use of antithrombotic agents withacabrutinibmay further increase the risk of bleeding. In clinical trials, major bleeding occurred in 2.7% of patients taking acalabrutinib but not antithrombotic agents and in 3.6% of patients taking acalabrutinib but not antithrombotic agents. Consider the risks and benefits of coadministering antithrombotic agents with acalabrutinib and monitor patients for signs of bleeding. Depending on the type of surgery and risk of bleeding, consider the pros and cons of stopping medication before and 3-7 days after surgery.

3.Cytopenia. Patients with hematological malignancies receiving acalabrutinib developed grade 3 or 4 cytopenias, including neutropenia (23%), anemia (8%), thrombocytopenia (7%), and lymphopenia (7%). Grade 4 neutropenia occurred in 12% of patients. Monitor complete blood count regularly during treatment, Interrupt treatment, reduce dose, or discontinue treatment as needed.

4.Second primary malignant tumor. In clinical trials, 12%of 1029 patients exposed to acalabrutinib developed a second primary malignancy, including skin cancer and other solid tumors. The most common second primary malignancy is skin cancer, which is reported to occur in 6% of patients. Monitor patients with skin cancer and recommend avoiding sun exposure.

5.Atrial fibrillation and flutter. Of 1029 patients who received acalabrutinib, 1.1% developed grade 3 atrial fibrillation or flutter, and 4.1% of all patients developed all grades of atrial fibrillation or flutter. Patients with cardiac risk factors, hypertension, previous cardiac arrhythmias, and acute infections may be at increased risk. Monitor for arrhythmia symptoms (e.g., palpitations, dizziness, syncope, difficulty breathing) and treat appropriately. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0